BACTI_B: Profitability maintained in Q3 2025, with BD rebound and strong wound management growth

About this update from Bactiguard Holding Ab

Q3 2025 saw profitability and clinical progress, though revenue declined year-over-year due to high prior-year comparisons and currency headwinds. BD partnership rebounded, while wound management showed 8% YTD growth and is expected to deliver double-digit growth long-term.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bactiguard Holding Ab